[BIC-announce] Special Seminar - Tuesday, May 3, 2016 - 1:30 p.m. - deGrandpre Communication Centre

[Grace Flynn, Ms.]

Special Seminar
Speaker:  Michael Sundstrom, PhD
Karolinska University Hospital/Karolinska Institutet - Sweden

Title:  Enabling Drug Discovery through an Open-Source Target Discovery Public-Private Partnership

Date:  Tuesday, May 3, 2016

Place:  de Grandpre Communications Centre

Time: 1:30 p.m.

-------------------------------------------------

Michael Sundström, PhD
Michael Sundstrom received his PhD from Uppsala, followed by PostDoctoral studies at the Karolinska Institutet. From 1993-2000 he was at Pharmacia as Director for structure based drug design and oncology R&D portfolio management. Between 2001 and 2003 he held senior positions at the Swedish Biotechs Actar and Biovitrum. In 2003 he joined the Structural Genomics Consortium (SGC) at the University of Oxford, as Chief Scientist. In 2007 he assumed the position as Managing Director for the Novo Nordisk Foundation Center for Protein Research (Copenhagen). From end of 2011, we was VP Discovery Research at Karolinska Development. He then re-joined the SGC and is since mid-2014 Scientific Director for European Initiatives, leading an IMI consortium focused on target validation in inflammatory diseases.
Abstract
The number of first in class therapies has remained constant for decades, often less than 10 per year. For such new medicines for pioneer targets, the level of attrition in Phase 2 proof-of-concept clinical studies remains the biggest hurdle. This is in large part due to the poor correlation of results from commonly used model systems compared to the the clinical realities.
Thus, the use of disease models based on human samples is critical to increase our understanding of pathophysiology. However, securing regular access to well-annotated samples from patients is challenging to organize, raises ethical issues and requires new organizational models, involving academic and pharmaceutical industry researchers, clinicians and disease foundations.
Within the SGC Open-Source Target Discovery Partnership, our aim is to define and validate under- explored protein targets by profiling high quality chemical and antibody probes in patient-cell derived assays in inflammation, oncology and CNS disorders, providing biomarker and phenotypic read-outs from test systems that more accurately mimic the disease itself.
References
The promise and peril of chemical probes. Arrowsmith CH et al. Nat Chem Biol. 2015 Jul 21;11(8):536-41
Preclinical target validation using patient-derived cells. Edwards AM, Arrowsmith CH, Bountra C, Bunnage ME, Feldmann M, Knight JC, Patel DD, Prinos P, Taylor MD and Sundström M (2015).
Nature Reviews Drug Discovery. 2015 Mar;14(3):149-50
Contact Details
Phone:             +46 70 65 44 662
E-mail:             michael.sundstrom at ki.se <mailto:michael.sundstrom at ki.se> michael.sundstrom at thesgc.org<mailto:michael.sundstrom at thesgc.org>

Ms. Grace Flynn

Montreal Neurological Institute
3801 University Street, Room 636
Montreal, Quebec  H3A 2B4
T: 514-398-5359
F: 514-398-8248
Grace.flynn at mcgill.ca<mailto:Grace.flynn at mcgill.ca>
www.mni.mcgill.ca<http://www.mni.mcgill.ca>



-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://www.bic.mni.mcgill.ca/pipermail/bic-announce/attachments/20160427/7fa6ad98/attachment-0001.html>
-------------- next part --------------
A non-text attachment was scrubbed...
Name: Special Seminar Michael Sundstrom May 3, 2016.pdf
Type: application/pdf
Size: 98083 bytes
Desc: Special Seminar Michael Sundstrom May 3, 2016.pdf
URL: <http://www.bic.mni.mcgill.ca/pipermail/bic-announce/attachments/20160427/7fa6ad98/attachment-0001.pdf>